Market Overview

UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Dropout Assumptions

Related AEGR
Aegerion Pharmaceuticals Grants 56.923K Stock Options Under Inducement Program, Exercise Price Of $13.19
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised the price target from $41.00 to $52.00.

In the report, Karnauskas noted, “AEGR has made assumptions for dropouts, which are key to their guidance of ending the year with 250-300 patients on Juxtapid. While our analysis suggests the co is well on track to beat the guidance, Aegerion wants to be conservative and get more data on dropouts ahead of modifying guidance. Dropout color might come later in the year when the co has more data (too soon for 1Q13 call). While the ph 3 saw 20% drop outs, AEGR expects much lower.”

Aegerion Pharmaceuticals closed on Wednesday at $38.49.

Latest Ratings for AEGR

Jul 2015JefferiesUpgradesHoldBuy
Jul 2015Guggenheim SecuritiesDowngradesNeutralSell
Oct 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters